Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary
pharmaceutical company, today announced it has appointed Jane
Eagleson and Tom Robitaille to its Board of Directors, effective
immediately. These appointments expand the Board to eight
directors, five of whom are independent.
“Together, Jane and Tom bring a combined 60 years of global
animal health experience to our Board of Directors,” stated
Chairman and CEO Gerald Solensky Jr. “The addition of these two
independent directors ensures Zomedica will continue to benefit
from diverse but complementary perspectives, skills and insights as
we continue to build the business.”
Jane EaglesonA veterinarian with more than 30
years of experience in animal health pharmaceutical development,
Eagleson is currently Vice President of Clinical and Regulatory
Affairs at Nexvet Biopharma (Nasdaq:NVET), a veterinary
biotherapeutics company. She concurrently serves, since January
2013, as owner of Bleecker Street Consulting, an animal health
consulting firm that specializes in pharmaceutical development
strategy in North America, Europe and the Oceania markets.
From September 2007 through December 2012, Eagleson held various
leadership positions with Argenta, a pharmaceutical contract
research and contract manufacturing organization. She joined
Argenta as Head of Clinical Research and Development and elevated
to Head of Growth Strategies where she assumed overall ownership of
the company’s strategic plan.
Prior to that, Eagleson served in several senior director roles
with Pfizer, Inc. from December 1999 through February 2007,
leaving the company as Senior Director of Asian Business
Development where she was based in India and responsible for
strategic planning and execution of Asian business initiatives for
both animal health and human health organizations.
Before Pfizer, Eagleson was a Director with Merial from 1991 to
1997 and served as Research Veterinarian with Merck Animal Health
from 1985 to 1991. She has a Master of Veterinary Science in
immunology from Massey University and Bachelor of Veterinary
Science (U.S. doctor of veterinary medicine equivalent) from the
University of Sydney. She has also authored more than 35
publications in peer reviewed journals.
Tom RobitailleA results-focused international
business leader with 30 years of animal health experience,
Robitaille is currently Vice President of Veterinary Channel
Development at Blue Buffalo Company (Nasdaq:BUFF), a premium,
all-natural pet food company.
Prior to that, Robitaille held various director level and senior
management positions during his 19-year career with the animal
health pharmaceutical company Vetoquinol SA Inc. Robitaille was the
Americas Group Director from September 2006 through October 2015,
where he managed affiliates and regional distributors in Canada,
USA, Mexico and Brazil. From October 2004 to October 2006 he was
responsible for veterinary pharmaceutical operations in the United
Kingdom, Ireland, Belgium, and the Netherlands as Managing
Director. He also served as Director of International Development
from October 2001 through September 2004, where he contributed to
an increase in sales and profit in Eastern Europe, Asia Pacific,
Africa, and Latin America.
Before Vetoquinol, Robitaille was a Product Manager with Elanco,
the animal health division of Eli Lilly and Company, and prior
thereto, started his animal health career serving in various sales
and marketing positions throughout Canada, USA, Europe and the
Middle East with Sandoz, a generic pharmaceuticals company.
Robitaille has a Master of Business Administration from the
University of Warwick and Bachelor of Science degree from Concordia
University.
About ZomedicaWith U.S. operations based in Ann
Arbor, Michigan, Zomedica is a veterinary pharmaceutical company
targeting health and wellness solutions for companion animals
(canine, feline and equine) through a ground-breaking approach that
focuses on the unmet needs of clinical veterinarians. Zomedica is
building a diversified portfolio of products comprised of the
discovery, development and commercialization of innovative drugs
alongside novel drug delivery systems, devices and diagnostics.
With multiple clinical veterinarians in executive management, it is
Zomedica’s mission to give veterinarians the opportunity to lower
costs, increase productivity, and grow revenue while better serving
the animals in their care. For more information, visit
www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: sign up for investor, product and service alerts
at www.ZOMEDICA.com
- LinkedIn: www.linkedin.com/company/zomedica
Reader AdvisoryNeither TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of the release.
Except for statements of historical fact, this news release
contains certain "forward-looking information" within the meaning
of applicable securities law. Forward-looking information is
frequently characterized by words such as "plan", "expect",
"project", "intend", "believe", "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Although we believe that the expectations
reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be
correct. We cannot guarantee future results, performance or
achievements. Consequently, there is no representation that the
actual results achieved will be the same, in whole or in part, as
those set out in the forward-looking information.
Forward-looking information is based on the opinions and
estimates of management at the date the statements are made, and
are subject to a variety of risks and uncertainties and other
factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking
information. Some of the risks and other factors that could cause
the results to differ materially from those expressed in the
forward-looking information include, but are not limited to:
uncertainty as to whether our strategies and business plans will
yield the expected benefits; availability and cost of capital; the
ability to identify and develop and achieve commercial success for
new products and technologies; the level of expenditures necessary
to maintain and improve the quality of products and services;
changes in technology and changes in laws and regulations; our
ability to secure and maintain strategic relationships; risks
pertaining to permits and licensing, intellectual property
infringement risks, risks relating to future clinical trials,
regulatory approvals, safety and efficacy of our products, the use
of our product, intellectual property protection and the other risk
factors disclosed under our profile on SEDAR at www.sedar.com.
Readers are cautioned that this list of risk factors should not be
construed as exhaustive.
The forward-looking information contained in this news release
is expressly qualified by this cautionary statement. We undertake
no duty to update any of the forward-looking information to conform
such information to actual results or to changes in our
expectations except as otherwise required by applicable securities
legislation. Readers are cautioned not to place undue reliance on
forward-looking information.
Zomedica Investor Relations Contact
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630
Zomedica Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555
BLUE BUFFALO PET PRODUCTS, INC. (NASDAQ:BUFF)
Historical Stock Chart
From Aug 2024 to Sep 2024
BLUE BUFFALO PET PRODUCTS, INC. (NASDAQ:BUFF)
Historical Stock Chart
From Sep 2023 to Sep 2024